SEC Form 4 · accession 0001237899-15-000017
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Brown
Director
Period of report
Feb 20, 2015
Accepted (ET)
Feb 23, 2015 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 20, 2015 | M | 1,000 | $57.11 | A | 1,000 | D | |
| Common StockF1 | Feb 20, 2015 | S | 1,000 | $422.72 | D | 0 | D | |
| Common Stock | holding | — | — | — | 18,349 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $57.11 | Feb 20, 2015 | M | 1,000 | D | — | Jan 3, 2022 | Common Stock | 1,000 | 8,000 | D |
Explanation of responses
- F1Represents volume-weighted average price of sales of 1,000 shares of Company stock on February 20, 2015 at prices ranging from $422.66 to $422.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 20, 2015 at each separate price.
- F2The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.